Reactive Oxygen Species (ROS)-Responsive Biomaterials for the Treatment of Bone-Related Diseases

Reactive oxygen species (ROS) are the key signaling molecules in many physiological signs of progress and are associated with almost all diseases, such as atherosclerosis, aging, and cancer. Bone is a specific connective tissue consisting of cells, fibers, and mineralized extracellular components, and its quality changes with aging and disease. Growing evidence indicated that overproduced ROS accumulation may disrupt cellular homeostasis in the progress of bone modeling and remodeling, leading to bone metabolic disease. Thus, ROS-responsive biomaterials have attracted great interest from many researchers as promising strategies to realize drug release or targeted therapy for bone-related diseases. Herein, we endeavor to introduce the role of ROS in the bone microenvironment, summarize the mechanism and development of ROS-responsive biomaterials, and their completion and potential for future therapy of bone-related diseases.

AMA FROM AYURVEDIC AND MODERN PERSPECTIVE

Agni is one of most powerful transformative principles of Ayurveda. Deranged Agni leads to the formation of Ama. Ama is responsible for causing most of the diseases in human beings. The disease produced, clinically mani- fests itself in form of various signs and symptoms. These signs and symptoms are the principal tools for a physi- cian to diagnose the disease and treat it promptly. On the basis of these symptoms, all diseases can be classified in Samavastha and Niramavastha. If an objective Parameter that could measure the severity of Ama is searched, it will prove to be an advantage for the physician, who could then catch the cause (Ama) and save patients from this harmful disease entity. A definite line of treatment of Ama can be planned after considering the symptoms and severity of the condition. Keeping this approach, the review is carried out to understand Ama from Ayurvedic and Modern perspectives. After reviewing it can be concluded that Ama has no direct correlation in modern science but can best be equated to 'toxins'. They may be endotoxins like enzymes, hormones, catalysts, etc. when these are unable to function properly or entirely, different metabolites are formed which are not acquired by the body. On further process these go on accumulating in different systems, affecting the normal mechanism of that respective system or exotoxins produced by some bacteria or micro-organism when they enter into the body. Keyword: Agni, Ama, Toxin

A REVIEW ARTICLE ON THE PHYSIOLOGICAL IMPORTANCE OF SAMANA VAYU IN RELATION TO THE ENTERIC NERVOUS SYSTEM

Ayurveda is a science that has been around for thousands of years and has proven to be beneficial to humans. Ayurveda is based on the tridosha theory. Vata, one of three doshas, plays an essential and major part in both healthy and unhealthy conditions, according to acharya sushruta dosha, dhatu and mala maintain our body. There are five types of vata- prana, udan, samana, vyan and apaan vayu. Among these five doshas samana vayu is situated near jatharagni and circulate all over the GIT tract. It helps in the division of essence and waste products, as well as the movement of the gastrointestinal tract, by stimulating the agni. In the body, jatharagni takes the form of pachak pitta, one of the pitta subtypes. Agnimandhya is responsible for all diseases, as we all know. The fire is fueled by samana vayu, who keeps it balanced. As a result, samana vayu might be regarded to play a specialized role in digestion. All of the samana vayu's functions can be compared to the physiological functions of the enteric nervous system and the sympathetic and parasympathetic supply of the Autonomic nervous system to the gastrointestinal tract. In this article, an attempt is made to correlate the physiological activity of samana vayu with the enteric nervous system. Keywords: Samana vayu, Prana vayu, Apan vayu, Sacral Segment.

ANALISIS PENEMPATAN TPS DI KECAMATAN PAMEKASAN BERBASIS SISTEM INFORMASI GEOGRAFIS

Abstrak: Penelitian ini bertujuan untuk menentukan Tempat Pembuangan Sementara (Sampah) yang ada di kecamatan pamekasan. Manfaat pada penelitian ini dapat meningkatkan kesadaran masyarakat tentang pentingnya kebersihan dilingkungan sekitar dan tershindar dari segala penyakit dan dapat dijadikan bahan pertimbangan untuk memberikan pelayanan lebih baik lagi terhadap masyarakat. Khususnya untuk membangun Tempat Pembuangan Sementara (Sampah) yang ada dikecamatan pamekasan. Metode penelitian kualitatif deskriptif ini dengan pengumpulan data, wawancara, observasi dan dokumentasi. Hasil penelitian berupa tempat sampah sementara, pembuangan samentara (sampah) berdasarkan hasil penelitian kriteria penempatan TPS / TPS 3R sudah sesuai dalam pasal 20 permen PU nomer 03/PRT/M/2013, maka di temukan 12 desa untuk penempatan TPS yang ada di kecamatan pamekasan, dengan jumlah tempat sampah 77 TPS. Kata Kunci: Lingkungan; Penentuan; SIG; (Sampah) TPS Abstract: This study aims to determine the Temporary Disposal Place (Garbage) in Pamekasan sub-district. The benefits of this study can increase public awareness about the importance of cleanliness in the surrounding environment and avoid all diseases and can be taken into consideration to provide better service to the community. Especially to build Temporary Disposal Sites (Garbage) in the Pamekasan sub-district. This descriptive qualitative research method uses data, observation, and documentation. The results of the study were temporary trash cans, waste disposal based on the results of the research, the criteria for placing TPS / TPS 3R were in accordance with article 20 of the PU Candy number 03 / PRT / M / 2013, so 12 villages were found to place TPS in Pamekasan sub-district , with the TOTAL 77 TPS trash cans. Keywords: determination; environment; of GIS; TPS (waste)

Clinical Treatment and Prognostic Analysis of Patients with Aneurysmal Subarachnoid Hemorrhage

Subarachnoid hemorrhage (SAH) is a serious disease caused by blood flow into the subarachnoid space due to rupture of blood vessels. All diseases that cause intracranial hemorrhage are the cause of subarachnoid hemorrhage. Among them, due to the particularity of intracranial blood vessels, intracranial blood vessels are more prone to aneurysms than other parts. Therefore, the incidence of aneurysmal subarachnoid hemorrhage (aSAH) is extremely high. The purpose of this article is to study the clinical treatment and prognosis analysis of aSAH patients. This article first summarizes the current status of SAH research at home and abroad and summarizes its potential value and significance. On this basis, an in-depth study of the clinical treatment of aSAH patients has been carried out. The physiological mechanism and clinical general differences of aSAH were studied and analyzed. This article systematically describes the application of CTP in the treatment and prognosis analysis of aSAH patients. Then, it will use a comparative analysis method, interdisciplinary method, and other research forms to carry out experimental research on the theme of this article. Research shows that rebleeding and blood sodium are the main factors for cerebral ischemia caused by aSAH.

Immunocorregating properties of propolis and their composite forms

Gastrointestinal and respiratory diseases of young farm animals account for the largest percentage of all diseases. Currently, vaccines have been developed and successfully used for the specific prevention of diseases of infectious etiology, but it is not always possible to develop immunity of sufficient intensity, since vaccination without immunostimulation does not contribute to sufficient antibody formation. One of the important tasks of practical veterinary medicine was to find environmentally safe immunocorregulating substances that do not have a suppressive effect on the body. It was established that the drug ferran activated hematopoietic reactions of the body. Ferran in combination with enterozyme restores immunopoiesis and erythropoiesis to the indicators of physiological norms. The combined use of enterozyme with propolis hasda high immunostimulating effect, enhanced the productive phase of the immune response, removed the suppressive effect of the vaccine and increased the factors of natural and colonization resistance of the intestine.

Dysfunction of the mucous membrane in the pathogenesis of chronic diseases of the nasal cavity

Performing not only respiratory, but also protective, olfactory, aesthetic and a number of other functions, the nose is an important part of the upper respiratory tract. The mucous membrane of the nasal cavity is the first protective barrier of the body that protects against the effects of adverse environmental factors, carrying out warming, purification and neutralization of the inhaled air. This mission is provided by the activity of the multilayered columnar ciliated epithelium, consisting of three main types of cells: ciliate, goblet and basal. The main protective mechanism in the nasal cavity is mucociliary clearance, carried out by means of nasal mucus and beating of cilia unidirectional towards the nasopharynx with a frequency of up to 1000 per minute. Violation of the integrity and disruption of the physiological functions of the mucous membrane of the nasal cavity leads to the development of pathological processes, which in turn can lead to a failure in the work of other organs and systems of the body. To date, about 16-18% of all diseases of the ENT organs are chronic forms of rhinitis. According to the ICAR classification, which is based on the pathophysiological mechanisms of the development of rhinitis, allergic and non-allergic forms are distinguished. Common to various forms is the effect of certain factors on the mucous membrane of the nasal cavity and, as a consequence, a violation of the mechanisms of its work.One of the forms of chronic rhinitis, caused by thinning of the mucous membrane and severe disorders of mucociliary transport, is atrophic rhinitis. The main symptoms of the disease are dryness, the formation of crusts in the nasal cavity, periodic bleeding. The approach to the treatment of acute and chronic processes against the background of atrophic changes in the nasal cavity should be comprehensive and aimed at restoring the physiological functions of the mucous membrane and the mechanisms of mucociliary transport.

Oral soft-tissue sarcomas diagnosed in an oral pathology service: a 16year experience

Objective: This study analyzed the prevalence and clinic-pathological features of soft-tissue sarcomas diagnosed in a single-center of oral pathology from a School of Dentistry in Brazil. Materials and methods: All consecutive cases of intra-oral soft-tissue sarcomas diagnosed between January of 2002 and December of 2018 were retrieved from the files; patient data (sex, age and race) and characteristics of the lesions (site, size, clinical aspect and duration of injury) were collected. Results: Among a total of 62,255 biopsies diagnosed in the studied period, soft-tissue oral sarcomas comprised 76 cases (0.12%). Kaposi sarcoma, rhabdomyosarcoma, leiomyosarcoma encompassed 64.5% of the cases, and 53% of these were diagnosed as Kaposi Sarcoma. Male patients were more affected (59.2%) and white patients comprised 50%. In general, 39.4% of the patients were between 21-40yo. Conclusion: Soft-tissue sarcomas are rare in oral soft-tissue and in our pathology service, they comprised only 0.12% of all diseases diagnosed in the studied period. Kaposi sarcoma was the most frequent, followed by leiomyosarcoma and rhabdomyosarcoma. Thus, it is important for stomatologists and pathologists to be aware of their characteristics when examining oral mucosa, mainly their peculiarities regarding patient’s age, clinical appearance, and site of occurrence.

Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States

Background/objectives: The COVID-19 pandemic led to a dramatic reduction of in-person medical care in the general population; however, impacts have not been well-characterized for patients with hematologic malignancies. This study assessed the impact of COVID-19 on healthcare delivery for patients with hematologic malignancies with documented active treatment. Methods: Patients from the nationwide Flatiron Health electronic health record (EHR)-derived de-identified database with confirmed diagnosis of AML, DLBCL, FL, MCL, CLL or MM, and age ≥ 18 years at initial diagnosis were included. To be included in the study, documented receipt of at least one systemic, non-maintenance line of therapy between March 1, 2016 - February 28, 2021 was required. Patients were categorized into treatment types within lines of therapy: Oral therapy (OralTx); outpatient infusions (OutPtTx); and inpatient infusions, including hematopoietic transplants and CAR-T cell therapy (InPtTx). Monthly visit rates were calculated as the number of visits (telemedicine or in-person [in-clinic treatment administration, vitals, and/or labs]) per active patient per 30-day standardized month. Only visits occurring within a line of therapy were included (i.e. during active therapy, excluding surveillance). Telemedicine was only available for abstraction during the pandemic period. We used time-series forecasting methods on pre-pandemic monthly visit rate data (March 2016 - February 2020) to estimate projected counterfactual visit rates between March 2020 - February 2021 (expected in-person visit rates if the pandemic had not occurred) for all diseases combined, each disease, and each treatment type. Differences between projected and actual monthly visit rates during the pandemic period were considered statistically significant and related to the pandemic if the actual visit rate was outside of the 95% prediction interval (PI) surrounding the projected estimate. Results: A total of 22,559 patients were included in this analysis (6,241 OralTx, 14,501 OutPtTx, 7,675 InPtTx): 4,069 AML, 3,641 DLBCL, 2,004 FL, 1,899 MCL, 4,574 CLL and 6,701 MM. There was a gradual downward trend in in-person visit rates across all diseases over the study period (March 2016 - February 2021, Figure) and general visit frequencies were lower for OralTx and higher for OutPtTx and InPtTx overall. For all diseases combined, early pandemic months (March - May 2020) saw an 18% (95% PI 8.9% - 25%) reduction in in-person visit rates averaged across OralTx and OutPtTx, with the projected rate being 1.5 (95% PI 1.3 - 1.6) visits per patient per month, compared to an actual rate of 1.2. Reductions in the in-person visit rates were significant for all 3 treatment types for MM, for OralTx for CLL, and for OutPtTx for MCL and CLL. Telemedicine visit rates were greatest for patients who received OralTx, followed by OutPtTx, then InPtTx, with greater use in the early pandemic months and subsequent decrease in later months. All in-person visit rates increased close to predicted rates in the later half of the pandemic period. Conclusions: In treatment of hematologic malignancies, overall documented in-person visit rates for patients on OralTx and OutPtTx significantly decreased during early pandemic months, but returned close to the projected rates later in the pandemic. There were no significant reductions in the overall in-person visit rate for patients on InPtTx. Variability in these trends by disease type was observed, with significant reductions in in-person visits impacting MM, CLL, and MCL. Figure. Visit rates over time according to treatment category Figure 1 Figure 1. Disclosures Lau: Roche: Current equity holder in publicly-traded company; Flatiron Health Inc: Current Employment. Wang: Roche: Current equity holder in publicly-traded company; Flatiron Health: Current Employment. Davidoff: AbbVie: Other: Family member consultancy; Amgen: Consultancy. Huntington: Bayer: Honoraria; Thyme Inc: Consultancy; Novartis: Consultancy; Flatiron Health Inc.: Consultancy; Genentech: Consultancy; SeaGen: Consultancy; Servier: Consultancy; AstraZeneca: Consultancy, Honoraria; TG Therapeutics: Research Funding; DTRM Biopharm: Research Funding; AbbVie: Consultancy; Pharmacyclics: Consultancy, Honoraria; Celgene: Consultancy, Research Funding. Calip: Pfizer: Research Funding; Roche: Current equity holder in publicly-traded company; Flatiron Health Inc: Current Employment. Shah: AstraZeneca: Research Funding; Seattle Genetics: Research Funding; Epizyme: Research Funding. Stephens: CSL Behring: Consultancy; TG Therapeutics: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy; Celgene: Consultancy; JUNO: Research Funding; Mingsight: Research Funding; Abbvie: Consultancy; Arqule: Research Funding; Adaptive: Membership on an entity's Board of Directors or advisory committees; Novartis: Research Funding; Epizyme: Membership on an entity's Board of Directors or advisory committees; Beigene: Membership on an entity's Board of Directors or advisory committees; Innate Pharma: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees, Research Funding. Miksad: Flatiron Health Inc: Current Employment, Current holder of individual stocks in a privately-held company; Roche: Current equity holder in publicly-traded company. Parikh: GNS Healthcare: Current holder of individual stocks in a privately-held company; Onc.AI: Current holder of individual stocks in a privately-held company; Humana: Honoraria, Research Funding; Nanology: Honoraria; Thyme Care: Honoraria; Flatiron Health Inc: Honoraria. Takvorian: Pfizer: Research Funding; Genentech: Consultancy. Neparidze: GlaxoSmithKline: Research Funding; Janssen: Research Funding; Eidos Therapeutics: Membership on an entity's Board of Directors or advisory committees. Seymour: Flatiron Health Inc: Current Employment; Janssen: Membership on an entity's Board of Directors or advisory committees; Roche: Current equity holder in publicly-traded company; Karyopharm: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees.